Association between opioid use and the development of diverticulitis (Opioids Diverticulitis)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS104164
• Study ID:
  104165
• Official title and acronym:
  Association between opioid use and the development of diverticulitis (Opioids Diverticulitis)
• DARWIN EU® study:
  No
• Study countries:
  Canada

  United Kingdom

  United States
• Study description:
  While opioid use has been established as a risk factor for diverticulitis, there is limited evidence on the association between opioid analgesics and diverticulitis. The objective of this study is to evaluate whether opioid use is associated with elevated risk of diverticulitis in patients indicated for treatment with opioids. We will carry out separate population-based cohort studies using administrative health databases from five Canadian provinces, the United Kingdom, and the United States. Results from the separate sites will be combined to provide an overall assessment of the risk of diverticulitis in users of opioids.
• Study status:
  Finalised

Research institutions and networks

Institutions

Lady Davis Institute

Clinical Practice Research Datalink (CPRD)

United Kingdom

University of British Columbia

University of Calgary Calgary, Canada; University of Manitoba Winnipeg, Canada; ICES Toronto, Canada; Saskatchewan Health Quality Council Saskatoon, Canada

Networks

Canadian Network for Observational Drug Effect Studies (CNODES)

Canada

Study timelines

Date when funding contract was signed

Planned:09/12/2022

Actual:09/12/2022

Study start date

Planned:20/03/2023

Actual:20/03/2023

Data analysis start date

Planned:20/03/2023

Actual:20/03/2023

Date of final study report

Planned:30/11/2023

Actual:08/08/2024

Sources of funding

Other

More details on funding

CNODES is a collaborating core network partner of CoLab, which is funded for query-related activity by Canada’s Drug Agency (CDA-AMC, grant number C222 360).

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable